Nordicus Partners 10-K Flags Going Concern, $4M Loss, and Control Weaknesses
NORD has more than doubled off its 52-week low of $1.25.
Summary
Nordicus Partners' 10-K discloses a going concern warning from its auditor, a $4.0 million net loss, and ineffective internal controls. With just $20,878 in cash, the pre-revenue biotech urgently needs additional funding.
Key Events · Earnings and Guidance · NORD
-
Going Concern Warning
Substantial doubt about the company's ability to continue as a going concern is raised in the auditor's report and Note 3, which point to an accumulated deficit of $50.8 million and a cash balance of just $20,878 as of March 31, 2026.
-
Financial Results
For fiscal 2026, the company posted a net loss of $4.0 million on zero revenue. Operating expenses reached $4.4 million, including $1.6 million in R&D, while cash used in operations totaled $4.3 million.
-
Internal Control Weakness
Management determined that disclosure controls and internal control over financial reporting were not effective, citing limited resources within the finance and accounting functions.
-
Director Resignation
After the fiscal year-end, director Andrew J. Ritter resigned from the board and all committees effective July 7, 2026, reducing the board's oversight capacity.
Analysis · NORD · Trade & Services
The annual report reveals that the auditor has raised substantial doubt about the company's ability to continue as a going concern. With only $20,878 in cash and an accumulated deficit of $50.8 million, cash burn is severe—$4.3 million was consumed by operations this year. Management also acknowledged that internal controls over financial reporting are ineffective, a consequence of limited accounting resources. For a pre-revenue biotech that depends on frequent capital raises, these are critical warning signs. Adding to governance uncertainty, director Andrew Ritter, who chaired the compensation committee, resigned after year-end. Survival now hinges on the company's ability to secure additional funding, likely through further dilutive stock sales.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.6% of the 330 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NORD was trading at $2.50 on OTC in the Trade & Services sector, with a market capitalization of approximately $47.2M. The 52-week trading range was $1.25 to $10.16. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.